Ranbaxy Launches First Biosimilar Of Infliximab Drug In India

Ranbaxy Laboratories Ltd., India's largest pharmaceutical company, Monday launched Infimab, the first 'Remicade (Infliximab) biosimilar in India. The product was launched at the Indian Rheumatology Association Conference (IRACON) in Chandigarh, in the presence of over a thousand rheumatologists and doctors from around the country.

Infimab is being introduced in the Indian market through a licensing partnership with EPRIRUS Biopharmaceuticals, Inc., a US and Swiss-based Biopharmaceutical company focused on the global development and commercialization of biosimilar monoclonal antibodies.

The company said Infimab would be manufactured by Reliance Life Sciences at a facility in Mumbai.

The innovator reference product is currently marketed for the treatment of inflammatory diseases including rheumatoid arthritis, Crohn's Disease, ankylosing spondylitis, ulcerative colitis, psoriatic arthritis and psoriasis.

Infimab marks Ranbaxy's entry into mAb (Monoclonal Antibodies) biologics, and will help the company provide greater access to quality biologic medicines in management of conditions like rheumatoid arthritis.

Ranbaxy Vice President & Country Head-India Region Rajeev Sibal said, "Infimab offers a new opportunity in the management of conditions like rheumatoid arthritis. The product has been developed as per global standards and delivers a similar clinical outcome to the innovator. It will be available in India at a very significant discount as compared to the innovator drug. More Indian patients will get the benefit of a world-class biologic treatment."

EPIRUS President and CEO Amit Munshi commented, "We are delighted to partner with Ranbaxy to bring Infimab to India. Infimab represents an affordable solution for patients and may expand patient access to this important medicine."

About Infimab (BOW015)

BOW015 is a biosimilar version of Infliximab, a biologic therapy marketed under the name Remicade. EPIRUS has previous reported positive Phase 1 and Phase 3 clinical data for BOW015. The phase 3 trial met its predefined endpoint and demonstrated the comparability of BOW015 to Remicade, as measured by ACR20 response in severe rheumatoid arthritis patients. The study also showed no meaningful differences between BOW015 and Remicade with regard to safety or immunogenicity.

At the BSE, Ranbaxy shares are currently trading at Rs.633.50, up 3.45 percent from the previous close.

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT